Pharmaceuticals, Biotechnology and Life Sciences
Aerie Pharmaceuticals has generated first quarter 2020 net revenues of $20.3 million, with net cash used in operating activities for the quarter ended March 31, 2020 on a U.S. GAAP basis totaled approximately $41.8 million, resulting in $264.7 million in cash and cash equivalents and investments as of March 31, 2020.
Conference Call and Webcast Today, November 6th, at 5:00 p.m. ET DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), has completed patient enrollment in its Phase 2 clinical trial of AR-1105 in…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
European Commission will in about two months decide on the Committee for Medicinal Products for Human Use’s positive opinion, recommending approval of Rhokiinsa in EU, developed by Aerie Pharmaceuticals, for reduction of elevated intraocular pressure in adult patients.
Aerie Pharmaceuticals has submitted a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA), to be allowed to produce Rocklatan in Ireland, to be sold USA.
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class…